⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
302 patients with HER2- metastatic breast cancer and germline BRCA mutation randomized 2:1 to olaparib 300mg BID vs standard chemotherapy (capecitabine, eribulin, or vinorelbine). Median PFS 7.0 vs 4.2 months (HR 0.58, 95% CI 0.43–0.80, p<0.001). Response rate 59.9% vs 28.8%. Grade 3+ AEs lower with olaparib (36.6% vs 50.5%). Funded by AstraZeneca (OlympiAD).
Coeff. authors = avg(0.40, 0.70) = 0.55
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.55, 0.95) = 0.55← lowest dominates
Alert signal : eoc → Coefficient forced to 0.3
Expression of Concern published
Final coefficient : 0.55
Final score = 44.0/52.8 × 0.55 × 100 = 46/100
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations det…
Antoniou A — 2003 · American journal of human genetics
Contrasted resultsRibociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Hortobagyi GN — 2016 · The New England Journal of Medicine
Contrasted resultsThe benefits and harms of breast cancer screening: an independent review.
Marmot MG — 2012 · Lancet (London, England)
Contrasted resultsCirculating tumor cells, disease progression, and survival in metastatic breast cancer.
Cristofanilli M — 2004 · The New England Journal of Medicine
Contrasted resultsEfficacy of bilateral prophylactic mastectomy in women with a family history of breast …
Hartmann LC — 1999 · The New England journal of medicine